Literature DB >> 3350733

Evaluation of unplanned interruptions in radiotherapy treatment schedules.

R D Lindberg1, K Jones, H H Garner, B Jose, W J Spanos, D Bhatnagar.   

Abstract

One of the major radiobiological interests has been to maximize the effectiveness of the time-dose relationship in the clinical setting. Current explorations include altered fractionation schedules, multiple daily fractions and hypofractionation. Patient compliance to standard radiotherapy treatment schedules is taken for granted. To evaluate the true rate of compliance, the charts of all new patients treated from July 1, 1984 through June 30, 1985 were reviewed. The overall incidence of unplanned interruptions was 54% (361/668). The frequency of interruptions is significantly higher in patients treated to the primary site as compared to those treated for metastasis (59.8% and 35.6% respectively). The duration of the interruptions varied: 12.7% of the patients missed only 1 day, 25% missed 2 to 5 days, 38% had interruptions totalling 6-15 days, and in 24% the total exceeded 15 days. The most frequent cause of the unplanned interruptions was a rest resulting from unusually adverse tissue reactions (46.8%-169/361). Although this study has documented that unplanned interruptions are a major problem, the impact on local control and survival cannot be determined from our data. A retrospective review of multi-institutional studies such as those conducted by the Patterns of Care or RTOG might show that one of the major causes of failure is unplanned interruptions.

Entities:  

Mesh:

Year:  1988        PMID: 3350733     DOI: 10.1016/0360-3016(88)90103-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

2.  The "rocky treatment course": identifying a high-risk subgroup of head and neck cancer patients for supportive interventions.

Authors:  Horia Vulpe; Janet Ellis; Shao Hui Huang; Eshetu G Atenafu; Raymond W Jang; Gary Rodin; Jolie Ringash
Journal:  Support Care Cancer       Date:  2016-11-04       Impact factor: 3.603

3.  A novel nitroxide is an effective brain redox imaging contrast agent and in vivo radioprotector.

Authors:  Ryan M Davis; Anastasia L Sowers; William DeGraff; Marcelino Bernardo; Angela Thetford; Murali C Krishna; James B Mitchell
Journal:  Free Radic Biol Med       Date:  2011-05-25       Impact factor: 7.376

4.  High-dose rate intracavitary irradiation for carcinoma of the uterine cervix. The adverse effect of treatment prolongation.

Authors:  M Chatani; Y Matayoshi; N Masaki; T Inoue
Journal:  Strahlenther Onkol       Date:  1997-07       Impact factor: 3.621

5.  Radiation therapy for early glottic carcinoma (T1N0M0). The adverse effect of treatment interruption.

Authors:  M Chatani; Y Matayoshi; N Masaki; T Teshima; T Inoue
Journal:  Strahlenther Onkol       Date:  1997-10       Impact factor: 3.621

Review 6.  [Delays and treatment interruptions: difficulties in administering radiotherapy in an ideal time-period].

Authors:  Carmen González San Segundo; Felipe A Calvo Manuel; Juan Antonio Santos Miranda
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

7.  Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy.

Authors:  Clayton B Hess; Dominique L Rash; Megan E Daly; D Gregory Farwell; John Bishop; Andrew T Vaughan; Machelle D Wilson; Allen M Chen
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-04       Impact factor: 6.223

8.  Radiotherapy interruption due to holidays adversely affects the survival of patients with nasopharyngeal carcinoma: a joint analysis based on large-scale retrospective data and clinical trials.

Authors:  Cheng Xu; Kai-Bin Yang; Rui-Jia Feng; Lei Chen; Xiao-Jing Du; Yan-Ping Mao; Wen-Fei Li; Qing Liu; Ying Sun; Jun Ma
Journal:  Radiat Oncol       Date:  2022-02-19       Impact factor: 3.481

9.  Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making.

Authors:  Haley K Perlow; Vincent Cassidy; Benjamin Farnia; Deukwoo Kwon; Adam W Awerbuch; Stephanie Ciraula; Scott Alford; Jacob Griggs; Joseph A Quintana; Raphael Yechieli; Stuart E Samuels
Journal:  Adv Radiat Oncol       Date:  2018-09-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.